Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

UMMS Affiliation

Laboratory of Nucleic Acid Vaccines; Department of Medicine, Division of Infectious Diseases and Immunology

Publication Date


Document Type



AIDS Vaccines; Adolescent; Adult; HIV Antibodies; HIV Envelope Protein gp120; Human Experimentation; Humans; Immunoglobulin G; Interferon-gamma; Middle Aged; Neutralization Tests; T-Lymphocytes; Vaccines, DNA


Life Sciences | Medicine and Health Sciences


An optimally effective AIDS vaccine would likely require the induction of both neutralizing antibody and cell-mediated immune responses, which has proven difficult to obtain in previous clinical trials. Here we report on the induction of Human Immunodeficiency Virus Type-1 (HIV-1)-specific immune responses in healthy adult volunteers that received the multi-gene, polyvalent, DNA prime-protein boost HIV-1 vaccine formulation, DP6-001, in a Phase I clinical trial conducted in healthy adult volunteers of both genders. Robust cross-subtype HIV-1-specific T cell responses were detected in IFNgamma ELISPOT assays. Furthermore, we detected high titer serum antibody responses that recognized a wide range of primary HIV-1 Env antigens and also neutralized pseudotyped viruses that express the primary Env antigens from multiple HIV-1 subtypes. These findings demonstrate that the DNA prime-protein boost approach is an effective immunization method to elicit both humoral and cell-mediated immune responses in humans, and that a polyvalent Env formulation could generate broad immune responses against HIV-1 viruses with diverse genetic backgrounds.

DOI of Published Version



Vaccine. 2008 Feb 20;26(8):1098-110. Epub 2008 Jan 10. Link to article on publisher's site

Journal/Book/Conference Title


Related Resources

Link to Article in PubMed

PubMed ID